We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 45% below its sector, cheaper than its peers on earnings.
Established in 2010 and based in Seoul, South Korea, EuBiologics Co., Ltd. is a biopharmaceutical company dedicated to developing and supplying essential vaccines for epidemics and antibiotic resistance within the country. Its product portfolio includes Euvchol, an oral vaccine for cholera prevention, and CRM197, a diphtheria toxin-mutant vaccine. Beyond its vaccine offerings, the company provides comprehensive, customized services for biopharmaceuticals derived from mammalian and microbial cells, guiding clients through various project stages such as cell line development, GMP production, validation, and regulatory assistance. EuBiologics operates advanced facilities equipped for the manufacturing of protein-based therapeutics and antibodies, with a particular specialization in recombinant biological products and antibody treatments. Additionally, the company offers expertise in process, formulation, and analytical method development, provides licensing consulting, and delivers a range of contract testing services, including lot release, stability, raw material, and method validation.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 206650.KQ and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
